Athira Pharma Inc (ATHA) Stock Price, Quote & News

Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 620 8501

Website: www.athira.com

Address:

18706 North Creek Parkway, Suite 104, Bothell, United States

jbrowny Dec. 19 at 12:23 AM

$ATHA anyone holding this over night is absolute mad. I’ve seen this play out Time and time again…. GL all!!

0 · Reply

Bonanza2252003 Dec. 19 at 12:17 AM

$ATHA I’m taking more of these bozos money before I cover 🤣 But as always . You’re the master 👍

0 · Reply

doctorslopadopolis Dec. 19 at 12:05 AM

$ATHA

0 · Reply

Iiii1ii Dec. 19 at 12:01 AM

$ATHA Delisting

1 · Reply

iRocket Dec. 18 at 11:52 PM

$ATHA 🚀🚀🚀🚀🚀 I got in early a.m. and it just hit scanners again. 3x back to back to back

0 · Reply

topstockalerts Dec. 18 at 11:34 PM

Top Gainers $$AFJKU $AFJK $ATHA $ZNB

0 · Reply

Stock_Catcher Dec. 18 at 11:25 PM

$RDAC.X anotha one..... 86% Crazy day today even when super slow sentiment.... $SMX 160+ break to 185 $AFJK 33 break to 82 $ATHA 6.60 to 8.35 $VIVK 71%. Link to join where I help 1 on 1 on price action using my experience https://www.youtube.com/@StockCatcher/join

0 · Reply

JHSSSS Dec. 18 at 11:24 PM

$ATHA Any scientists out there that know the data or addressable market??

0 · Reply

_SpaceFloater Dec. 18 at 11:15 PM

That was a banger man, Made some nice profit :) I would say drop that @ICEMAN_ALERTS a FOLLOW. Dude has been on fire with the early entries 🔥 good buyz: $AFJK $ATHA $SOC $ZNB

0 · Reply

Stock_Boomer Dec. 18 at 11:07 PM

$ATHA gap n go.

0 · Reply

Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript

Dec 18, 2025, 1:09 PM EST - 6 hours ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 7:02 AM EST - 12 hours ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Sep 11, 2025, 9:00 AM EDT - 3 months ago

Athira Pharma Announces Reverse Stock Split

May 13, 2025, 11:00 AM EDT - 7 months ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025, 4:05 PM EDT - 7 months ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 10 months ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 4, 2024, 8:48 AM EDT - 1 year ago

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Jul 31, 2024, 8:05 AM EDT - 1 year ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

May 29, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming June Conferences

May 17, 2024, 5:00 PM EDT - 1 year ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 15, 2024, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma to Participate in Upcoming May Conferences

Apr 15, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Mar 8, 2024, 7:00 AM EST - 1 year ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Feb 22, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Jul 17, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 6, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

May 22, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 8, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Apr 25, 2023, 4:01 PM EDT - 2 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Mar 28, 2023, 1:00 AM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 23, 2023, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 6, 2023, 7:00 AM EST - 3 years ago

Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences

Feb 1, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication in Journal of Alzheimer's Disease Highlighting Need for Novel Alzheimer's Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway

Jan 31, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer

Jan 5, 2023, 7:00 AM EST - 3 years ago

Athira Pharma Provides 2023 Pipeline Outlook

Dec 21, 2022, 7:00 AM EST - 3 years ago

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

jbrowny Dec. 19 at 12:23 AM

$ATHA anyone holding this over night is absolute mad. I’ve seen this play out Time and time again…. GL all!!

0 · Reply

Bonanza2252003 Dec. 19 at 12:17 AM

$ATHA I’m taking more of these bozos money before I cover 🤣 But as always . You’re the master 👍

0 · Reply

doctorslopadopolis Dec. 19 at 12:05 AM

$ATHA

0 · Reply

Iiii1ii Dec. 19 at 12:01 AM

$ATHA Delisting

1 · Reply

iRocket Dec. 18 at 11:52 PM

$ATHA 🚀🚀🚀🚀🚀 I got in early a.m. and it just hit scanners again. 3x back to back to back

0 · Reply

topstockalerts Dec. 18 at 11:34 PM

Top Gainers $$AFJKU $AFJK $ATHA $ZNB

0 · Reply

Stock_Catcher Dec. 18 at 11:25 PM

0 · Reply

JHSSSS Dec. 18 at 11:24 PM

$ATHA Any scientists out there that know the data or addressable market??

0 · Reply

_SpaceFloater Dec. 18 at 11:15 PM

That was a banger man, Made some nice profit :) I would say drop that @ICEMAN_ALERTS a FOLLOW. Dude has been on fire with the early entries 🔥 good buyz: $AFJK $ATHA $SOC $ZNB

0 · Reply

Stock_Boomer Dec. 18 at 11:07 PM

$ATHA gap n go.

0 · Reply

WallStreetBuyDip Dec. 18 at 10:54 PM

$ATHA Trading at $6.72, matching the highest point with a low of $2.29, while average volume stands at 272,634. Recent volume peaked at 60M shares on Dec 18.

0 · Reply

TreasureBoyX Dec. 18 at 10:47 PM

Ticker JHJL has only 76 watchers on Stocktwits. Literally no one is watching it. Imo, JHJL could be the next 200-1000% china ramp and dump. The Hong Kong mafia has been squeezing tickers like this one lately. $TLRY $AFJK $ATHA $SOC $VIVK gains to JLHL

1 · Reply

Rampageusa Dec. 18 at 10:45 PM

$AFJK, $ATHA round two started ...

0 · Reply

Godwins26 Dec. 18 at 10:38 PM

Stronger bulls Watchlist ⬆️ $VIVK $AFJK $SOC $ATHA

0 · Reply

Bonanza2252003 Dec. 18 at 10:36 PM

$ATHA And the last thing you dont understand is shorting bios doesn’t put them out of business . The lenders always give them more money . They pump and dump those shares on retail then they save enough too dump and drive the price down while shorting . The bio company doesn’t give a rats ass . They will give them more money and do the same thing over and over through every reverse split , this goes on endlessly . They are in it together , bio gets funding . Lender makes money . You kids think because a lender gave them money they must think the stock is valuable . That’s not how it works , company only cares about funding and lender always makes their money too . This is an endless cycle . The bio never goes out of business , they just do research forever repeating this process until maybe they actually discover something wich in reality very rarely ever happpens . These bios are research doctors , they don’t give a rats ass about share holders or Sp .

1 · Reply

TreasureBoyX Dec. 18 at 10:25 PM

We saw SMX from 3$ to 480$ We saw TGL from 6$ to 80$ We saw OCG from 3$ to 20$ Next one in line could be ticker JLHL! JLHL fits perfect into the china mafia squeeze profile. It only has a handful of watchers on Stocktwits, so this time you can be early. WARNING: The Hong-Kong gangsters might pump this hard! $AFJK $ATHA $SOC $ZNB $SGD - > > JLHL!

0 · Reply

Bonanza2252003 Dec. 18 at 10:21 PM

$ATHA Let me do some math for you . By the time this potential drug comes to market in 3 yeas ( if it ever does ) the float will be well over 100m ( maybe more ) . So now the 1B valuation is $10 a share and that’s assuming there are no reverse splits in that 3 years which there surely will be after that much dilution . Like I said kid . Learn the small cap bio game before you lose all your money . I’m done with my education session . Good luck .

1 · Reply

StockFlips Dec. 18 at 10:20 PM

$RAIN a leading provider of ionization precipitation generation technology, today announced that David Sylvester, Senior Vice President and Chief Financial Officer of Steelcase Inc., has joined the Company's Board of Directors. This strategic appointment brings extensive financial leadership and public company expertise to RET's board as the Company accelerates the commercialization and scaling of its weather enhancement technology globally. 🤯 👉 Stacked for success, I like it. Long term for me here, not a flip (unless it randomly goes 300% obviously which it may very well do just that soon). Watching $ASNS as well small scaling here 3 day rule after dilution but I think it’s overdone. $ATHA $SOC strong runners today. $MNTS possible post RS pump here soon on low float. Known runner

1 · Reply

Rampageusa Dec. 18 at 10:17 PM

$CETX and $ATHA also can double from here...Christmas is near by folks..

0 · Reply

SR_JACK Dec. 18 at 10:08 PM

$ATHA phenomenal trade from early entries! 💸🟢🔥📈 Got to stay ahead of the game!

0 · Reply

Bonanza2252003 Dec. 18 at 10:08 PM

$ATHA You missed the part about all their dilution coming and no product to sell for a few years and maybe never . Sure if the drug is good and gets through all the regulatory phases then gets marketed it will be worth a lot . Are you holding for 3 years and through massive dilution to find that out . 🤣. You’re a fool kid . I can’t help because you are clearly much smarter than I 🤣

0 · Reply

come_litaliano Dec. 18 at 10:03 PM

$ATHA This profit was enough for me for today.

1 · Reply

Market Cap	15.30M
Revenue (ttm)	0.00
Net Income (ttm)	-96.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,375,598
Avg Vol	23,646
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	62%
Beta	2.95
Analysts	Hold
Price Target	$4.00